BIOCQ
OTCM
Market cap0kUSD
Nov 20, Last price
0.00USD
1D
0.00%
1Q
100.00%
Jan 2017
-100.00%
IPO
-100.00%
Name
Biocept Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Biocept, Inc., established in 1997 and based in San Diego, California, was a molecular oncology diagnostics firm. Its primary business involved the development and commercialization of exclusive clinical laboratory assays within the United States. These advanced tests were engineered to detect elusive tumor cells and cell-free tumor DNA (ctDNA) from both blood and cerebrospinal fluid (CSF) samples. The insights provided by Biocept's cancer assays were instrumental for healthcare professionals, allowing them to pinpoint specific cancer-causing genetic mutations. This capability helped identify suitable cancer patients for targeted therapies, whether at the point of initial diagnosis, during disease progression, or for continuous monitoring to uncover resistance mechanisms. The company offered diagnostic solutions for a variety of solid tumor cancers, such as breast, non-small cell lung (NSCLC), gastric, colorectal, prostate, pancreaticobiliary, and ovarian cancers. Furthermore, Biocept extended specialized testing services for CSF tumor cells, ctDNA, and ctRNA to a diverse group of medical specialists, including medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, and pathologists. It also supplied clinical trial and research assistance to pharmaceutical and biopharmaceutical companies, along with clinical research organizations. Biocept participated in collaborations, notably with CLEARED4 to create a system for overseeing COVID-19 testing requirements and results for its clientele. Another partnership with Protean BioDiagnostics, Inc. aimed to evaluate the proficiency of its Target Selector molecular assay in ascertaining EGFR status in NSCLC patients. However, Biocept, Inc. voluntarily initiated liquidation proceedings by filing for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware on October 13, 2023.
Key people
Philippe Marchand
Chief Operating Officer · since 2022
Cory Dunn
Senior Vice President of Commercial Operations · since 2020
Robert Walsh
Principal Accounting Officer, Vice President, Controller · since 2023
Darrell Taylor
Chief Legal Officer and Chief Compliance Officer · since 2022
Nathaniel Sweed
Medical Director · since 2023
Marsha Chandler
Independent Director · since 2013
Bruce Gerhardt
Independent Chairman of the Board · since 2023
M. Faye Wilson
Lead Independent Director · since 2022
Legal address
C/O Corporation Service Company
251 Little Falls Drive
Wilmington, DE 19808
US
251 Little Falls Drive
Wilmington, DE 19808
US
Headquarters
5810 Nancy Ridge Drive
San Diego, CA 92121
US
San Diego, CA 92121
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||